{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:37:20Z","timestamp":1792647440728,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.blre.2024.101168","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:09:13Z","timestamp":1704373753000},"page":"101168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Chromosomal defects in multiple myeloma"],"prefix":"10.1016","volume":"64","author":[{"given":"Sarah E.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy N.","family":"Erber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2024.101168_bb0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijlh.12360","article-title":"Advances in the pathogenesis and diagnosis of multiple myeloma","volume":"37","author":"Chesi","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.blre.2024.101168_bb0010","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101168_bb0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2024.101168_bb0020","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.blre.2024.101168_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101168_bb0030","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101168_bb0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101168_bb0040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2024.101168_bb0045","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101168_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101168_bb0055","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101168_bb0060","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","article-title":"Cell of origin and genetic alterations in the pathogenesis of multiple myeloma","volume":"10","author":"Barwick","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.blre.2024.101168_bb0065","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2024.101168_bb0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas \u2014 current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101168_bb0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5603\/AHP.2021.0004","article-title":"Clinical implications of cytogenetic and molecular aberrations in multiple myeloma","volume":"52","author":"Goldman-Mazur","year":"2021","journal-title":"Acta Haematol Pol"},{"issue":"10","key":"10.1016\/j.blre.2024.101168_bb0080","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3324\/haematol.2012.081083","article-title":"Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma","volume":"98","author":"Van Wier","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.blre.2024.101168_bb0085","doi-asserted-by":"crossref","first-page":"732","DOI":"10.18632\/oncotarget.26589","article-title":"Poor overall survival in hyperhaploid multiple myeloma is defined by double-ht bi-allelic inactivation of TP53","volume":"10","author":"Ashby","year":"2019","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.blre.2024.101168_bb0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/leu.2016.253","article-title":"Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma","volume":"31","author":"Sawyer","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101168_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-019-0182-z","article-title":"Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations","volume":"9","author":"Peterson","year":"2019","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.blre.2024.101168_bb0100","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells","volume":"121","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101168_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2019004309","article-title":"Risk factors in multiple myeloma: is it time for a revision?","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2024.101168_bb0110","first-page":"2950","article-title":"Multiple myeloma with t(11;14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"17","key":"10.1016\/j.blre.2024.101168_bb0115","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood.2021014968","article-title":"Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features","volume":"139","author":"Cazaubiel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101168_bb0120","first-page":"2(e89)","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood","author":"Kalff","year":"2012","journal-title":"Cancer J"},{"issue":"13","key":"10.1016\/j.blre.2024.101168_bb0125","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.2022016212","article-title":"The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM","volume":"141","author":"Strong","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101168_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/864058","article-title":"The genetic architecture of multiple myeloma","volume":"2014","author":"Prideaux","year":"2014","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.blre.2024.101168_bb0135","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.21.01987","article-title":"In multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations","volume":"41","author":"Lannes","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101168_bb0140","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/hemato3020021","article-title":"What is genomic high-risk myeloma?","volume":"3","author":"Davies","year":"2022","journal-title":"Hemato"},{"key":"10.1016\/j.blre.2024.101168_bb0145","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/s41598-020-62885-0","article-title":"Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance","volume":"10","author":"Baysal","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.blre.2024.101168_bb0150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2024.101168_bb0155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/TACG.S262866","article-title":"Genetic predictors of mortality in patients with multiple myeloma","volume":"14","author":"Hassan","year":"2021","journal-title":"Appl Clin Genet"},{"issue":"9","key":"10.1016\/j.blre.2024.101168_bb0160","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologia"},{"key":"10.1016\/j.blre.2024.101168_bb0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101168_bb0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101168_bb0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-019-0226-4","article-title":"An acquired high-risk chromosome instability phenotype in multiple myeloma: jumping 1q syndrome","volume":"9","author":"Sawyer","year":"2019","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.blre.2024.101168_bb0180","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-22-3209","article-title":"Multiomic mapping of acquired chromosome 1 copy-number and structural variants to identify therapeutic vulnerabilities in multiple myeloma","volume":"29","author":"Boyle","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2024.101168_bb0185","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101168_bb0190","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2024.101168_bb0195","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.blre.2024.101168_bb0200","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101168_bb0205","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/bloodadvances.2018028530","article-title":"Impact of acquired del(17p) in multiple myeloma","volume":"3","author":"Lakshman","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101168_bb0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","article-title":"Natural history of multiple myeloma with de novo del(17p)","volume":"9","author":"Lakshman","year":"2019","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.blre.2024.101168_bb0215","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2024.101168_bb0220","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"Del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101168_bb0225","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","article-title":"The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma","volume":"102","author":"Thanendrarajan","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101168_bb0230","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/life12060812","article-title":"Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup","volume":"12","author":"Wiedmeier-Nutor","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.blre.2024.101168_bb0235","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1158\/1078-0432.CCR-21-0005","article-title":"The prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2024.101168_bb0240","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101168_bb0245","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2024.101168_bb0250","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/gcc.22977","article-title":"Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma","volume":"60","author":"Dalland","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2024.101168_bb0255","first-page":"13","article-title":"Multiple myeloma: heterogeneous in every way","author":"Schavgoulidze","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2024.101168_bb0260","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","article-title":"Molecular basis of clonal evolution in multiple myeloma","volume":"111","author":"Furukawa","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2024.101168_bb0265","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Sch\u00fcrch","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.blre.2024.101168_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.919278","article-title":"The role of clonal evolution on progression, blood parameters, and response to therapy in multiple myeloma","volume":"12","author":"Sandmann","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2024.101168_bb0275","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2012.226","article-title":"Minor clone provides a reservoir for relapse in multiple myeloma","volume":"27","author":"Magrangeas","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101168_bb0280","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/cancers14061430","article-title":"Biological characterization and clinical relevance of circulating tumor cells: opening the pandora\u2019s box of multiple myeloma","volume":"14","author":"Garc\u00e9s","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2024.101168_bb0285","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101168_bb0290","doi-asserted-by":"crossref","unstructured":"Heerema, N.A. Cytogenetic analysis of hematologic malignant diseases, in The AGT cytogenetics laboratory manual (4th ed), M.S. Arsham, Barch, M.J., Lawce, H.J., 2017, John Wiley & Sons, Inc.: Hoboken, New Jersey, USA. p. 499\u2013575.","DOI":"10.1002\/9781119061199.ch11"},{"issue":"01","key":"10.1016\/j.blre.2024.101168_bb0295","first-page":"38","article-title":"Molecular classification and risk stratification of myeloma. Hematology","volume":"31","author":"Bergsagel","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.blre.2024.101168_bb0300","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2141.1998.00951.x","article-title":"IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases","volume":"103","author":"Hernandez","year":"1998","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2024.101168_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-4608(85)90032-9","article-title":"The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders","volume":"18","author":"Dewald","year":"1985","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.blre.2024.101168_bb0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.blre.2024.101168_bb0315","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2024.101168_bb0320","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","article-title":"Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma","volume":"4","author":"Mellors","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101168_bb0325","first-page":"712","article-title":"Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques","volume":"136","author":"Hartmann","year":"2011","journal-title":"Hematopathology"},{"issue":"8","key":"10.1016\/j.blre.2024.101168_bb0330","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101168_bb0335","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/arpa.2012-0209-OA","article-title":"Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms","volume":"137","author":"Lu","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101168_bb0340","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajcp\/aqad108","article-title":"Superior detection rate of plasma cell FISH using FACS-FISH","volume":"161","author":"Gagnon","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2024.101168_bb0345","doi-asserted-by":"crossref","first-page":"8287","DOI":"10.1038\/s41598-022-11676-w","article-title":"Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma","volume":"12","author":"Ha","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2024.101168_bb0350","doi-asserted-by":"crossref","unstructured":"Lawce. H.J., S., J.S. Fluorescence in situ hybridization (FISH)), in The AGT Cytogenetics Laboratory Manual (4th ed), M.S. Arsham, Barch, M.J., Lawce, H.J., Editor. 2017, John Wiley & Sons, Inc.: Hoboken, New Jersey, USA. p. 717\u2013831.","DOI":"10.1002\/9781119061199.ch16"},{"issue":"4","key":"10.1016\/j.blre.2024.101168_bb0355","first-page":"183","article-title":"IGH: comparing variant fluorescent patterns produced by FISH probes","volume":"33","author":"Cote","year":"2007","journal-title":"J Assoc Genet Technolog"},{"key":"10.1016\/j.blre.2024.101168_bb0360","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13039-016-0263-7","article-title":"Target fluorescence in-situ hybridization (target FISH) for plasma cell enrichment in myeloma","volume":"9","author":"Ma","year":"2016","journal-title":"Mol Cytogenet"},{"issue":"4","key":"10.1016\/j.blre.2024.101168_bb0365","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5603\/AHP.2021.0073","article-title":"FISH diagnostics in plasma cell myeloma: recommendations and our own experience","volume":"52","author":"Woroniecka","year":"2021","journal-title":"Acta Haematol Pol"},{"key":"10.1016\/j.blre.2024.101168_bb0370","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1751-553X.2012.01433.x","article-title":"Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma","volume":"34","author":"Shin","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"10.1016\/j.blre.2024.101168_bb0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.hemonc.2015.04.002","article-title":"Detection of 14q32 rearrangements in multiple myeloma, using simultaneous FISH analysis combined with immunofluorescence","volume":"8","author":"Abaza","year":"2015","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"5","key":"10.1016\/j.blre.2024.101168_bb0380","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clml.2012.05.003","article-title":"Risk stratification of plasma cell neoplasm: insights from plasma cell\u2013specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH","volume":"12","author":"Dong","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.blre.2024.101168_bb0385","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2353\/jmoldx.2006.050149","article-title":"Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence","volume":"8","author":"Cook","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.blre.2024.101168_bb0390","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/jclinpath-2012-201131","article-title":"Fluorescence in situ hybridisation analysis of bone marrow trephine biopsy specimens; an additional tool in the diagnostic armoury","volume":"66","author":"Neat","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2024.101168_bb0395","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000101712","article-title":"Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy","volume":"74","author":"Fend","year":"2007","journal-title":"Pathobiology"},{"issue":"11","key":"10.1016\/j.blre.2024.101168_bb0400","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.mpdhp.2020.08.005","article-title":"In situ hybridisation in tissue sections","volume":"26","author":"Chiecchio","year":"2020","journal-title":"Diagn Histopathol"},{"issue":"4","key":"10.1016\/j.blre.2024.101168_bb0405","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2353\/jmoldx.2007.070041","article-title":"Detection of genetic alterations by immunoFISH analysis of whole cells extracted from routine biopsy material","volume":"9","author":"Mattsson","year":"2007","journal-title":"J Mol Diagn"},{"issue":"3","key":"10.1016\/j.blre.2024.101168_bb0410","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PAI.0b013e3180de490f","article-title":"Simultaneous phenotyping and genotyping (FICTION-methodology) on paraffin sections and cytologic specimens","volume":"16","author":"Bzorek","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.blre.2024.101168_bb0415","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.25391","article-title":"Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Haematol"},{"key":"10.1016\/j.blre.2024.101168_bb0420","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1002\/ajh.25420","article-title":"Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.blre.2024.101168_bb0425","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cyto.b.22023","article-title":"Analysis of human chromosomes by imaging flow cytometry","volume":"100","author":"Stanley","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.blre.2024.101168_bb0430","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymeth.2017.11.003","article-title":"Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia","volume":"134-135","author":"Hui","year":"2018","journal-title":"Methods"},{"issue":"7","key":"10.1016\/j.blre.2024.101168_bb0435","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.pathol.2021.12.296","article-title":"Imaging flow cytometry shows monosomy 17 in circulating plasma cells in myeloma","volume":"54","author":"Lam","year":"2022","journal-title":"Pathology"},{"issue":"11","key":"10.1016\/j.blre.2024.101168_bb0440","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/jcp-2022-208230","article-title":"IGH cytogenetic abnormalities can be detected in multiple myeloma by imaging flow cytometry","volume":"76","author":"Hui","year":"2023","journal-title":"J Clin Pathol"},{"issue":"7","key":"10.1016\/j.blre.2024.101168_bb0445","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s10038-023-01136-2","article-title":"Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma","volume":"68","author":"Tsukamoto","year":"2023","journal-title":"J Hum Genet"},{"issue":"7","key":"10.1016\/j.blre.2024.101168_bb0450","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s10038-023-01155-z","article-title":"Enhanced multi-FISH analysis of immunophenotyped plasma cells by imaging flow cytometry","volume":"68","author":"Erber","year":"2023","journal-title":"J Hum Genet"},{"issue":"8","key":"10.1016\/j.blre.2024.101168_bb0455","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cyto.a.22852","article-title":"Development of a robust Immuno-S-FISH protocol using imaging flow cytometry","volume":"89","author":"Fuller","year":"2016","journal-title":"Cytometry A"},{"issue":"9","key":"10.1016\/j.blre.2024.101168_bb0460","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/cyto.a.22101","article-title":"Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension","volume":"81","author":"Minderman","year":"2012","journal-title":"Cytometry A"},{"key":"10.1016\/j.blre.2024.101168_bb0465","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-143323","article-title":"Detection of del(17p) in hematological malignancies by imaging flow cytometry","volume":"136","author":"Erber","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2024.101168_bb0470","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tibtech.2017.12.008","article-title":"Diagnostic potential of imaging flow cytometry","volume":"36","author":"Doan","year":"2018","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.blre.2024.101168_bb0475","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/D1LC01043C","article-title":"Deep imaging flow cytometry","volume":"22","author":"Huang","year":"2022","journal-title":"Lab Chip"},{"key":"10.1016\/j.blre.2024.101168_bb0480","first-page":"91","article-title":"Identification of prognostically relevant chromosomal abnormalities in routine diagnostics of multiple myeloma using genomic profiling","volume":"13","author":"Kjeldsen","year":"2016","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.blre.2024.101168_bb0485","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cancergen.2020.12.003","article-title":"Implementation of cytogenomic microarray with plasma cell enrichment enables better abnormality detection and risk stratification in patients with plasma cell neoplasia than conventional cytogenetics and fluorescence in situ hybridization","volume":"252-253","author":"Chen","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.blre.2024.101168_bb0490","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.critrevonc.2019.07.016","article-title":"Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies","volume":"142","author":"Berry","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2024.101168_bb0495","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41436-021-01214-w","article-title":"Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Shao","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.blre.2024.101168_bb0500","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41375-019-0378-z","article-title":"European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms","volume":"33","author":"Rack","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101168_bb0505","first-page":"189","article-title":"Next-generation sequencing for clinical management of multiple myeloma: ready for prime time?","volume":"10","author":"Bolli","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2024.101168_bb0510","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.path.2023.01.005","article-title":"Molecular diagnostics of plasma cell neoplasms","volume":"16","author":"Fitzpatrick","year":"2023","journal-title":"Surg Pathol"},{"issue":"7","key":"10.1016\/j.blre.2024.101168_bb0515","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/1940-6207.CAPR-11-0432","article-title":"Key principles and clinical applications of \u201cnext-generation\u201d DNA sequencing","volume":"5","author":"Rizzo","year":"2012","journal-title":"Cancer Prevention Research (Philadelphia, Pa.)"},{"key":"10.1016\/j.blre.2024.101168_bb0520","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2024.101168_bb0525","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101168_bb0530","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2024.101168_bb0535","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","article-title":"Chromothripsis as a pathogenic driver of multiple myeloma","volume":"123","author":"Maura","year":"2022","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.blre.2024.101168_bb0540","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-20-1395","article-title":"Designing evolutionary-based interception strategies to block the transition from precursor phases to multiple myeloma","volume":"27","author":"Maura","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2024.101168_bb0545","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2024.101168_bb0550","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2024.101168_bb0555","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932852","article-title":"Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy","volume":"12","author":"Ferla","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2024.101168_bb0560","doi-asserted-by":"crossref","first-page":"862","DOI":"10.5858\/arpa.2021-0088-OA","article-title":"Interlaboratory analytical validation of a next-generation sequencing srategy for clonotypic assessment and minimal residual disease monitoring in multiple myeloma","volume":"146","author":"Medina","year":"2022","journal-title":"Arch Pathol Lab Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:45Z","timestamp":1759437105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":112,"alternative-id":["S0268960X24000018"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101168","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chromosomal defects in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101168"}}